Adial Pharmaceuticals Inc (ADIL NASDAQ) stock market data APIs
$0.4068
-0.09(-22.1%)
as of July 10, 2025
Try our APIs with
free plan!
Adial Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
Prev. Close
0.4068
Open
0.3165
High
0.414
Low
0.3165
52 wk Range
0.22-1.37
Market Cap
6 468 K
Shares Outstanding
15 776 K
EPS
-0.34
Beta
1.185
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adial Pharmaceuticals Inc data using free add-ons & libraries
Get Adial Pharmaceuticals Inc Fundamental Data
Adial Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -8 706 163
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.495
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adial Pharmaceuticals Inc News
New
Adial Pharmaceuticals files patent update for alcohol disorder treatment
GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a micro-cap pharmaceutical company with a market capitalization of $5 million, announced on Wednesday it has filed an update to its provisi...
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
GLEN ALLEN, Va., July 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck
Company Logo The global alcohol use disorder market is experiencing significant growth, driven by increasing demand for innovative and personalized treatments, and the integration of digital health t...
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
(RTTNews) - What's driving the momentum in the following stocks? Vor Bio, Inc. (VOR) has secured ex-Greater China rights from RemeGen Co., Ltd. to develop and commercialize Telitacicept, a novel dual...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
